UK – AstraZeneca’s heart failure treatment recommended by NICE for expanded use

AstraZeneca’s (AZ) Forixga (dapagliflozin) has been recommended for extended use by the National Institute for Health and Care Excellence (NICE), meaning adult patients with heart failure (HF) can benefit from the treatment regardless of their left ventricular ejection fraction status (LVEF).

Forxiga, sold as Farxiga in certain markets, has previously been recommended by NICE as a treatment option for HF patients with reduced ejection fraction (HFrEF) which is equal to or less than 40%.

An estimated 920,000 people live with HF in the UK, with more than 550,000 patients having a confirmed diagnosis in England alone.

Roughly half of all HF patients have mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF), characterised by an especially high burden of symptoms and physical limitations.

Previously, the only therapies recommended for this patient population have been for the management of symptoms and comorbidities…